Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. (Q39096331)

9 September 2017

Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. (English)

1 reference

9 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gema Ruiz-Hurtado

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Luis Miguel Ruilope

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Antonios A Lazaridis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

20 January 2017

1 reference

Nature Reviews Endocrinology

9 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

365-374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28106149%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2016.209

10 June 2020

exact match

0 references

cites work

Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

The burden of blood pressure-related disease: a neglected priority for global health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

The metabolic syndrome: a glance at its history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Executive summary: Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Clinical practice. Systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Importance of sustained and "tight" blood pressure control in patients with high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

New insights from ADVANCE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Redefining Blood-Pressure Targets--SPRINT Starts the Marathon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

EFFECTS OF BLOOD-PRESSURE MEASUREMENT BY THE DOCTOR ON PATIENT'S BLOOD PRESSURE AND HEART RATE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

21 January 2018

Hypertension Guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Practice Guidelines For Primary Care Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Standards of medical care for patients with diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Executive summary: Standards of medical care in diabetes--2013

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

SPRINT Trial Results: Latest News in Hypertension Management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Snapshot Hemodynamics and Clinical Outcomes in Hypertension: Precision in the Measurements Is Key.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

SPRINT, or False Start, Toward a Lower Universal Treated Blood Pressure Target in Hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Successes of SPRINT, but Still Some Hurdles to Cross

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.209

Effect of valsartan on the incidence of diabetes and cardiovascular events

31 March 2020

1 reference

12 December 2020

1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension

1 reference

12 December 2020

International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke

1 reference

12 December 2020

Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes

1 reference

12 December 2020

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

12 December 2020

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group

1 reference

12 December 2020

Blood pressure targets for hypertension in people with diabetes mellitus

1 reference

12 December 2020